Viatris Inc business relationships

Companies named in Viatris Inc’s 10-K filed 2026-02-26, and public companies whose annual reports name Viatris Inc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.6 / 10
AI naming: 100 / 100
Agent readiness: 30 / 100
AI adoption: 0 / 100

Named in Viatris Inc’s annual report 4

PFIZER INC (PFE)Customer7.7
“| | | Manufacturing and Supply Agreement, dated as of November 16, 2020, by and between Viatris Inc. (as Manufacturer) and Pfizer Inc. (as Customer), filed as Exhibit 10.6 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^ |” SEC filing
PFIZER INC (PFE)Supplier7.7
“| | | Manufacturing and Supply Agreement, dated as of November 16, 2020, by and between Pfizer Inc. (as Manufacturer) and Viatris Inc. (as Customer), filed as Exhibit 10.5 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.^ |” SEC filing
IQVIA HOLDINGS INC. (IQV)Supplier6.7
“Unless otherwise indicated, industry data included in this Item 1 are sourced from IQVIA Holdings Inc. and are for the twelve months ended November 2025 and Viatris product and other company data included in this Item 1 are from internal sources and are as of November 30, 2025.” SEC filing
Biocon LimitedPartner5.2
“• receipt of $245.0 million in deferred consideration from the Biocon Biologics Transaction, and net cash of $52.7 million collected on behalf of various partners, including Biocon Biologics, which are included in Other items, net.” SEC filing

Companies whose annual reports name Viatris Inc 8

LEXICON PHARMACEUTICALS, INC. (LXRX)names it as licensee4.7
“The Company further evaluated its stated intent in the Viatris Licensing Agreement to enter into a separate manufacturing and supply agreement related to supply of the licensed products to Viatris.” SEC filing
LEXICON PHARMACEUTICALS, INC. (LXRX)names it as licensor4.7
“We entered into an exclusive license agreement with Viatris Inc. in October 2024 under which we granted Viatris an exclusive, royalty-bearing right and license to develop and commercialize sotagliflozin in the licensed territory.” SEC filing
LEXICON PHARMACEUTICALS, INC. (LXRX)names it as partner4.7
“The Company also concluded that the Viatris Licensing Agreement is not a collaborative agreement under ASC 808, as Viatris is responsible for all regulatory and commercialization activities for sotagliflozin in the Licensed Territory as well as conducting any additional clinical trials required to o...” SEC filing
LEXICON PHARMACEUTICALS, INC. (LXRX)names it as supplier4.7
“We and Viatris have entered into a manufacturing and supply agreement pursuant to which we supply Viatris' development and commercial requirements of sotagliflozin and Viatris pays an agreed upon transfer price for such supply.” SEC filing
AEON Biopharma, Inc. (AEON)names it as licensor4.6
“...ived approval for, its injectable botulinum toxin, daxibotulinumtoxinA, for the therapeutic indications of cervical dystonia and adult upper limb spasticity, and which has also entered into a collaboration and license agreement with Viatris Inc. to develop and commercialize a biosimilar to Botox®. |” SEC filing
Opus Genetics, Inc. (IRD)names it as licensee4.6
“potential milestone and royalty payments from the agreements with Viatris or from other license agreements entered into the future; however, the attainment of milestones or level of sales required to earn significant royalty payments is” SEC filing
Opus Genetics, Inc. (IRD)names it as licensor4.6
“Viatris License Agreement” SEC filing
Opus Genetics, Inc. (IRD)names it as partner4.6
“We already have a collaboration with Viatris for the development and” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.